An interventional study of Anatabine in Inflammation, sponsored by Roskamp Institute Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-28.
Sponsored by Roskamp Institute Inc. · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,173 studies in Inflammation with a site in United States — 161 open to participants now, 214 under way, 6 of them phase 3. Inflammation · United States.
Among the 1,173 studies in Inflammation with a site in United States, this one is the 183rd largest by enrollment of the 956 interventional ones that give a count, is one of 54 that started in 2011, is one of 462 with no phase, and was the 374th registered.
3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.
Browse Inflammation studies →161 of the 1,173 studies in Inflammation with a site in United States are open now. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Nebraska · Sites in United States
Ages 1 mo–3 yrs
Daniel Moriarity · Sites in United States
Ages 18+
University of Arkansas · Sites in United States
Ages 21–75 · Healthy volunteers
Vanderbilt University Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 160 · Phase 2 241 · Phase 3 91 · Phase 4 73
First in 1978; this study’s year is marked. 54 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 50 across 2,586 interventional studies indexed under Inflammation.
Median enrollment 45 across the 956 interventional studies, 90 across the 214 observational. Of the 887 that completed or were terminated, 307 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
164 of 1,173 have an industry lead sponsor. The 10 most frequent:
Roskamp Institute Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Roskamp Institute Inc. has 1 study filed under Inflammation — fewer than ten, so there is no comparison to draw.
78 of the studies in Inflammation with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT05699174Phase 3Major Extremity Trauma Research ConsortiumPO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation | 2027-09 |
| NCT03675724Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | 2026-11 |
| NCT03430037Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | 2026-11 |
Add all 78 to your calendar (.ics) → With an account.
Among the 1,173 studies in Inflammation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators are studying a dietary supplement called anatabine in a lozenge form named RCP006. The main purpose of this study is to evaluate the effects of this dietary supplement on normal human inflammatory function. The investigators will see this effect in volunteers who have markers of higher levels of inflammation to begin with. The investigators anticipate that anatabine will reduce markers of inflammation. Therefore the investigators are looking for volunteers with high blood levels of C-reactive Protein (CRP) and will monitor the blood CRP levels at several time points throughout the study.
The investigators are studying a dietary supplement called anatabine which for the purposes of this study has been made into lozenges and named RCP006. Anatabine, the only active ingredient of RCP006, occurs throughout the world in the human food chain. Anatabine has been in the human food supply and in human use for centuries. Humans are exposed to anatabine in tobacco products and common and widely consumed food crops such as potatoes, peppers, eggplants and tomatoes. The main purpose of this study is to evaluate the effects of this dietary supplement on normal human inflammatory function. Compounds that are chemically similar to anatabine have been shown to reduce inflammatory responses, and laboratory studies show anti-inflammatory properties for anatabine. The investigators want to explore this further in human studies to see if anatabine can maintain normal levels of inflammatory function. The investigators will see this effect more easily if the investigators look at the effects of anatabine in volunteers who have markers of higher levels of inflammation to begin with. The investigators anticipate that anatabine will reduce markers of inflammation. To look for inflammation the investigators will test blood levels of a protein called C-reactive protein. C-reactive protein (CRP) is a protein found in the blood, the levels of which rise in response to inflammation. Therefore the investigators are looking for volunteers with high blood levels of CRP and will monitor the blood CRP levels at several timepoints throughout the study. The investigators will also collect blood samples to measure other indicators of inflammation, and to measure blood levels of anatabine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1mg anatabine in a mint-flavored mannitol lozenge
Also known as: RCP006
Blood levels of hsCRP
Time frame: Days 1, 14, 42, 70
Blood levels of inflammatory markers
Time frame: Days 1, 14, 42, 70
The record gives a start of May 2011, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Roskamp Institute Inc.